References
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the diagnosis, management and prevention of COPD. Updated December 2011. www goldcopd org 2011 [cited 2012 Aug 30]
- Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol 1996;42:697-705
- Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care 2005;50:1313-21
- Girodet PO, Raherison C, Abouelfath A, et al. [Real-life use of inhaler devices for chronic obstructive pulmonary disease in primary care]. Therapie 2003;58:499-504
- Laube BL, Janssens HM, de Jongh FH, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011;37:1308-31
- Terzano C. Dry powder inhalers and the risk of error. Respiration 2008;75:14-15
- Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration 2008;75:18-25
- Al-Showair RA, Tarsin WY, Assi KH, et al. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med 2007;101:2395-401
- Janssens W, VandenBrande P, Hardeman E, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J 2008;31:78-83
- Byron PR. Drug delivery devices: issues in drug development. Proc Am Thorac Soc 2004;1:321-8
- United States Pharmacopeial Convention. Aerosols, metered dose inhalers, and dry powder inhalers. USP30-NF25. Rockville, MD: 2009
- Montuschi P. Pharmacological treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2006;1:409-23
- Montuschi P, Macagno F, Valente S, et al. Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD. Curr Med Chem 2012; Sep 3. [Epub ahead of print]
- Cazzola M, Matera MG, Lotvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005;14:775-83
- Pavkov R, Mueller S, Fiebich K, et al. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin 2010;26:2527-33
- Chapman KR, Fogarty CM, Peckitt C, et al. Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis 2011;6:353-63
- ICRP. ICPR publication 66: Human respiratory tract model for radiological protection. A report of a task group of the International commission on radiological protection. Ann ICRP 1994;24:1-482
- Van Der PJ, Eijsvogel MM, Kuipers BF, et al. Comparison of the Diskus inhaler and the Handihaler regarding preference and ease of use. J Aerosol Med 2007;20:38-44
- Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:600-12
- Kumon M, Machida S, Suzuki M, et al. Application and mechanism of inhalation profile improvement of DPI formulations by mechanofusion with magnesium stearate. Chem Pharm Bull (Tokyo) 2008;56:617-25
- Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:588-99
- Newman SP, Chan HK. In vitro/in vivo comparisons in pulmonary drug delivery. J Aerosol Med Pulm Drug Deliv 2008;21:77-84
- Berg E, Madsen J, Bisgaard H. In vitro performance of three combinations of spacers and pressurized metered dose inhalers for treatment in children. Eur Respir J 1998;12:472-6
- Svartengren K, Lindestad P, Svartengren M, et al. Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am J Respir Crit Care Med 1995;152:32-7
- Weuthen T, Roeder S, Brand P, et al. In vitro testing of two formoterol dry powder inhalers at different flow rates. J Aerosol Med 2002;15:297-303